Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma
Authors:
Open Access
- 20 June 2016
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 78 (2) , 313-323
Abstract
Purpose Systemic therapy has improved rhabdomyosarcoma event-free and overall survival; however, approximately 40 % of patients will have progressive or recurrent disease which is difficult to cure and remains a considerable challenge. Minimal progress has been made in improving outcomes for metastatic or relapsed RMS due to a lack of effective therapeutic agents. Targeted therapies are likely to be incorporated into regimens which rely on conventional cytotoxic chemotherapy. A system to evaluate novel combinations of interest is needed. Methods In this study, we explored 8 agents, 5 that are routinely used or similar to agents used in the clinical management of RMS and 3 biologically targeted agents with novel mechanisms of action, the Wee1 inhibitor AZD1775, the tyrosine kinase inhibitor cabozantinib, and the proteasome inhibitor bortezomib. All were tested individually at clinically achievable concentrations for activity in 4 RMS cell lines and then for potential synergy in two-drug combinations. Results We found single-agent activity in five of the agents (or their active metabolites) that constitute the standard of care in RMS and for AZD1775 with mean IC50 values of 207 ng/ml, well below clinically achievable levels. In addition, the combination of individual cytotoxic chemotherapeutics currently used for RMS demonstrated largely synergistic activity with higher, but clinically achievable concentrations of AZD1775 in our assays. Conclusions Prioritization of chemotherapeutics in RMS is possible using an in vitro system that can define novel drug combinations worthy of future investigation. AZD1775 exhibits single-agent activity, as well as synergy with conventional cytotoxic chemotherapy, and is a novel targeted agent that warrants further study in RMS.Keywords
Funding Information
- Pediatric Cancer Foundation
This publication has 30 references indexed in Scilit:
- Identification of Synergistic, Clinically Achievable, Combination Therapies for OsteosarcomaScientific Reports, 2015
- WEE1 Kinase As a Target for Cancer TherapyJournal of Clinical Oncology, 2015
- Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid TumorsJournal of Clinical Oncology, 2015
- Rapid Screening of Novel Agents for Combination Therapy in SarcomasSarcoma, 2013
- Epidemiology and therapies for metastatic sarcomaClinical Epidemiology, 2013
- WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic CatastropheClinical Cancer Research, 2011
- Results of the Intergroup Rhabdomyosarcoma Study Group D9602 Protocol, Using Vincristine and Dactinomycin With or Without Cyclophosphamide and Radiation Therapy, for Newly Diagnosed Patients With Low-Risk Embryonal Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology GroupJournal of Clinical Oncology, 2011
- Prognostic Factors in Metastatic Rhabdomyosarcomas: Results of a Pooled Analysis From United States and European Cooperative GroupsJournal of Clinical Oncology, 2008
- Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcomaEuropean Journal of Cancer, 2008
- Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitorsAdvances in Enzyme Regulation, 1984